OTC drug labeling format
This article was originally published in The Rose Sheet
Executive Summary
Use of a two-column format in the "Warnings" section of OTC labeling would allow for more information in the "Drug Facts" section and may help solve some of the space problems created by FDA's final rule, the Consumer Healthcare Products Association says in a May 6 letter to the agency. "The use of columns is a significant space saver" and "definitely allows the standard format and the modified format to be used for more SKUs, thereby helping to limit the number of potential exemptions," CHPA says. The letter follows an April 23 "feedback" meeting ("The Rose Sheet" May 3, pp. 8-9). CHPA says it will provide the agency with a more detailed submission but requests a quick turnaround response. The Cosmetic, Toiletry and Fragrance Association is preparing separate comments
You may also be interested in...
OTC Label Multiple Columns Suggested For Elongated Packaging By CHPA
FDA should allow the use of more than two columns to present required information on OTC labeling for products with long rectangular packaging, Consumer Healthcare Products Association Senior VP and Director of Science & Technology William Soller, PhD, suggested at a June 29 "feedback" meeting on the OTC labeling final rule was held in Rockville, Md.
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program